FY2017 EPS Estimates for FibroGen, Inc (FGEN) Boosted by William Blair

FibroGen, Inc (NASDAQ:FGEN) – Stock analysts at William Blair raised their FY2017 earnings estimates for shares of FibroGen in a research report issued to clients and investors on Thursday. William Blair analyst A. Hsieh now forecasts that the biopharmaceutical company will post earnings of ($1.64) per share for the year, up from their prior estimate of ($2.02). William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for FibroGen’s Q4 2017 earnings at ($0.15) EPS, Q1 2018 earnings at ($0.51) EPS, Q2 2018 earnings at ($0.53) EPS, Q4 2018 earnings at ($0.60) EPS, FY2018 earnings at ($0.65) EPS, FY2019 earnings at $1.50 EPS and FY2020 earnings at ($1.82) EPS.

A number of other research firms have also commented on FGEN. Mizuho began coverage on FibroGen in a research report on Wednesday, October 4th. They set a “neutral” rating and a $61.00 price target on the stock. Stifel Nicolaus reaffirmed a “buy” rating and set a $80.00 price target on shares of FibroGen in a research report on Thursday, September 14th. Jefferies Group LLC reaffirmed a “buy” rating and set a $75.00 price target on shares of FibroGen in a research report on Tuesday, September 12th. Goldman Sachs Group, Inc. (The) downgraded FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price objective for the company. in a report on Friday, July 21st. Finally, BidaskClub downgraded FibroGen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $65.67.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://transcriptdaily.com/2017/11/15/fy2017-eps-estimates-for-fibrogen-inc-fgen-boosted-by-william-blair.html.

Shares of FibroGen (NASDAQ:FGEN) opened at $44.85 on Monday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.83 and a current ratio of 10.83. FibroGen has a 1 year low of $19.25 and a 1 year high of $60.15.

Several institutional investors and hedge funds have recently added to or reduced their stakes in FGEN. UBS Asset Management Americas Inc. acquired a new stake in shares of FibroGen in the first quarter valued at approximately $288,000. Parametric Portfolio Associates LLC acquired a new stake in shares of FibroGen in the first quarter valued at approximately $249,000. Principal Financial Group Inc. lifted its position in shares of FibroGen by 0.4% in the first quarter. Principal Financial Group Inc. now owns 136,045 shares of the biopharmaceutical company’s stock valued at $3,354,000 after buying an additional 504 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of FibroGen by 55.6% in the first quarter. Wellington Management Group LLP now owns 87,031 shares of the biopharmaceutical company’s stock valued at $2,146,000 after buying an additional 31,105 shares during the last quarter. Finally, Teachers Advisors LLC lifted its position in shares of FibroGen by 1.4% in the first quarter. Teachers Advisors LLC now owns 468,413 shares of the biopharmaceutical company’s stock valued at $11,546,000 after buying an additional 6,512 shares during the last quarter. 46.93% of the stock is owned by institutional investors.

In other FibroGen news, insider K Peony Yu sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $55.37, for a total value of $415,275.00. Following the completion of the transaction, the insider now directly owns 170,104 shares in the company, valued at $9,418,658.48. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Pat Cotroneo sold 2,851 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $49.45, for a total value of $140,981.95. Following the completion of the transaction, the vice president now owns 157,405 shares of the company’s stock, valued at $7,783,677.25. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 428,118 shares of company stock valued at $22,355,896. Corporate insiders own 14.90% of the company’s stock.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply